Iqymune

Human Normal Immunoglobulin, the active ingredient in Iqymune, is an immunoglobulin presented as a sterile solution for intravenous use. It provides passive immunity by supplying pooled IgG antibodies and is used in patients with immune deficiencies or certain autoimmune conditions. GNH USA supplies Iqymune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iqymune, a pooled human immunoglobulin, is employed in several immune‑related conditions where antibody support is required. - Primary immunodeficiency diseases: reduces infection frequency by supplying functional IgG. - Idiopathic thrombocytopenic purpura (ITP): raises platelet counts through immune modulation. - Kawasaki disease: lowers risk of coronary artery aneurysms in acute phase. - Chronic inflammatory demyelinating polyneuropathy (CIDP): improves muscle strength and functional ability. - Guillain‑Barré syndrome: accelerates recovery of nerve function.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever and chills: typical infusion‑related reactions. - Nausea or vomiting: may occur during or after infusion. - Fatigue: feeling of tiredness post‑administration. - Infusion‑related reactions: flushing, itching, or rash. - Hypertension or hypotension: blood pressure changes during infusion.

Serious or Rare Side Effects: - Thromboembolic events: clot formation in veins or arteries. - Acute renal failure: especially with high doses or pre‑existing kidney disease. - Aseptic meningitis: severe headache with neck stiffness. - Anaphylaxis: severe allergic reaction requiring immediate treatment. - Hemolysis: destruction of red blood cells. - Severe allergic reactions: including serum sickness.

Before initiating therapy, consider the following precautions: - Assess renal function: monitor creatinine and urine output. - Evaluate cardiovascular status: watch for hypertension or heart failure. - Screen for thrombotic risk: avoid in patients with active clotting disorders. - Review vaccination history: postpone live vaccines for at least 3 months after infusion. - Monitor for hemolysis: check hemoglobin and bilirubin levels. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection; avoid concurrent administration. - Anticoagulants (e.g., warfarin): can increase INR and bleeding risk. - High‑dose aspirin or NSAIDs: may exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclophosphamide): may alter efficacy of both agents. - Antibiotics (e.g., beta‑lactams): potential for reduced antibody activity. - Diuretics: monitor fluid balance and renal function during therapy.